Skip to main content

Advertisement

Fig. 1 | Radiation Oncology

Fig. 1

From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

Fig. 1

The cetuximab-taxane recurrency scheme. Shows a sketch of the cetuximab-taxan recurrency scheme and its time line. The regimen consists of operative debulking, postoperative brachytherapy and the simultaneous use of cetuximab and taxol. Brachytherapy was applied with a single dose of 2.5 Gy twice daily to a total dose of average 27.0 Gy

Back to article page